Affordable Prescriptions for Patients Act

What happened?

Proposal in Congress

  1. Committee on the Judiciary. Reported by Senator Grassley with amendments. Without written report.
  2. Passed/agreed to in Senate: Passed Senate with amendments by Unanimous Consent.

Affordable Prescriptions for Patients Act This bill limits in certain instances the number of patents that the manufacturer of a biologic drug can assert in a…

Read the details

What this means

Status
Proposal in Congress
What happened
Affordable Prescriptions for Patients Act This bill limits in certain instances the number of patents that the manufacturer of a biologic drug can assert in a lawsuit against a company seeking to sell a biosimilar version of that drug. (A biologic drug is produced through natural processes or isolated from natural sources. A biosimilar version is substantially similar to the original biologic, which is the reference product, and is often marketed as a less…
What to check next
See the latest action below for the next step in Congress.
Check the original record

About this record

Affordable Prescriptions for Patients Act This bill limits in certain instances the number of patents that the manufacturer of a biologic drug can assert in a lawsuit against a company seeking to sell a biosimilar version of that drug. (A biologic drug is produced through natural processes or isolated from natural sources. A biosimilar version is substantially similar to the original biologic, which is the reference product, and is often marketed as a less expensive alternative.) The bill's provisions apply to an existing framework that gives the biosimilar manufacturer an abbreviated path to Food and Drug Administration approval to sell the biosimilar. Specifically, if the biosimilar manufacturer completes certain actions under the framework, such as sharing certain information about its product with the reference product manufacturer, the bill limits the number of certain patents that the reference product manufacturer may assert in a lawsuit, such as patents that were filed more than four years after the reference product received market approval. The limit shall not apply to patents claiming certain methods for using the biologic drug. The court in which the infringement lawsuit is filed may increase the limit if justice so requires or if there is good cause for the increase.

Record details

Bill number
S. 1041
Congress
119
Introduced
2025-03-13
Sponsor
Sen. Cornyn, John [R-TX]
Committees
Judiciary Committee
Latest documented action
Held at the desk.

Documented actions

  1. Held at the desk.

  2. Received in the House.

  3. Message on Senate action sent to the House.

  4. Passed Senate with amendments by Unanimous Consent. (consideration: CR S4198-4199; text: CR S4199)

  5. Passed/agreed to in Senate: Passed Senate with amendments by Unanimous Consent.

  6. Placed on Senate Legislative Calendar under General Orders. Calendar No. 44.

  7. Committee on the Judiciary. Reported by Senator Grassley with amendments. Without written report.

  8. Committee on the Judiciary. Reported by Senator Grassley with amendments. Without written report.

Sources and related records

Source checked .